Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

This research study is looking into a new medicine, dazukibart, for people with muscle conditions called dermatomyositis (DM) and polymyositis (PM). These conditions cause muscles to become weak and can also cause a skin rash in DM. The study aims to understand how this new medicine works, if it can help improve symptoms, and if it is safe. Participants in the study will either receive the new medicine or a dummy medicine (placebo) through an IV drip once a month for about a year. By comparing these two groups, researchers hope to learn if dazukibart could be a helpful treatment option.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Pfizer
Objetivo de inscripción
318
Inicio
20 May 2023
Estimación de finalización
29 Jul 2030

¿De qué trata este estudio?

This study is investigating a new medicine called dazukibart for conditions known as idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM). These are rare conditions where your body's immune system mistakenly attacks your muscles, making them weak. This can make everyday activities like walking, climbing stairs, or getting up from a chair difficult. People with dermatomyositis also often get a distinctive skin rash.

The main goal of this study is to find out if dazukibart can help improve the muscle weakness and other symptoms of DM and PM, and importantly, if it is safe for people to use. To do this, researchers will give some participants the new medicine and others a 'placebo', which looks exactly like the study medicine but contains no active drug. This allows them to clearly see if any changes are due to the new medicine itself.

Understanding how dazukibart works could potentially lead to a new treatment option for people living with these challenging conditions. Your participation could help advance medical knowledge and potentially benefit others in the future.

Puntos clave

  • This study evaluates a new medicine (dazukibart) for dermatomyositis (DM) and polymyositis (PM).
  • It aims to understand if dazukibart is safe and effective for muscle weakness.
  • Participants will receive either dazukibart or a placebo via IV drip once a month.
  • The study lasts about 13 months and involves regular clinic visits.
  • Participation includes health checks and close monitoring by the study team.

¿Quién puede ser elegible?

To be considered for this study, you need to be an adult, aged 18 or over, and have been diagnosed with active dermatomyositis (DM) or polymyositis (PM). You should also be taking a steady dose of a common anti-inflammatory medicine (like a corticosteroid) or another type of medicine that calms your immune system, or both.

There are also some reasons why you might not be able to join. For example, if your muscle weakness is due to a different condition, or if you have certain other serious health issues like some cancers, severe infections, or other significant diseases that could make the study medicine unsafe for you. We also can't include people who have had certain organ transplants or serious heart or brain conditions recently.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have active dermatomyositis (DM) or polymyositis (PM)?
  3. Are you currently on a stable dose of certain anti-inflammatory or immune-calming medicines?
  4. Do you have any other serious health conditions like recent cancer, severe infections, or major heart/brain problems?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, it will last for about 13 months. During this time, you will have 15 visits to the study centre. At these visits, you will receive either the study medicine (dazukibart) or a placebo (a dummy medicine with no active ingredients). Both will be given through a drip into your vein (an IV infusion), which takes about an hour, and this will happen every four weeks for 48 weeks.

Throughout the study, the research team will regularly check your health, symptoms, and how you are responding to the treatment. This will involve physical exams, blood tests, and asking questions about how you are feeling. All these checks are done to monitor your safety and see how the medicine is working.

Riesgos y beneficios potenciales

Taking part in a study like this might offer potential benefits, such as receiving a new medicine that could help your condition or getting extra medical attention. However, there are also potential risks, as dazukibart is an experimental medicine, and we don't yet know all of its side effects. You might experience discomfort from injections or other procedures, or the medicine might not help your condition. It's important to remember that you can stop taking part in the study at any time, for any reason, without it affecting your usual medical care.

Locations (138)

  • Arizona Arthritis & Rheumatology Research, PLLC
    Código postal verificado
    Glendale, United States· Reclutamiento
  • Neuromuscular Research Center
    Código postal verificado
    Phoenix, Estados Unidos· Reclutamiento
  • Mayo Clinic Hospital
    Código postal verificado
    Phoenix, Estados Unidos· Reclutamiento
  • Mayo Clinic in Arizona - Scottsdale
    Código postal verificado
    Scottsdale, Estados Unidos· Reclutamiento
  • 200 UCLA Medical Plaza
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • UCLA Clinical & Translational Research Center (CTRC)
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • UCLA
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • Center for Clinical Research - Chapman Pavilion
    Código postal verificado
    Orange, Estados Unidos· Activo, no reclutando
  • UCI Douglas Hospital
    Código postal verificado
    Orange, Estados Unidos· Activo, no reclutando
  • UCI Health Center for Innovative Health Therapies
    Código postal verificado
    Orange, Estados Unidos· Activo, no reclutando
  • University of California - Irvine
    Código postal verificado
    Orange, Estados Unidos· Activo, no reclutando
  • Samir Macwan, M.D., Inc.
    Código postal verificado
    Rancho Mirage, United States· Reclutamiento

Preguntas comunes

What are dermatomyositis (DM) and polymyositis (PM)?

They are rare conditions where your immune system attacks your muscles, causing weakness and sometimes a skin rash (in DM).

¿Qué es un 'placebo'?

A placebo looks exactly like the study medicine but doesn't contain any active drug. It helps researchers see if the real medicine is effective.

¿Cómo se administrará el medicamento?

The medicine or placebo will be given through a drip into a vein (an IV infusion) at the study centre.

How long will I take part in the study?

You will be in the study for about 13 months, with visits to the study centre every four weeks.

¿Puedo abandonar el estudio si cambio de opinión?

Yes, you can leave the study at any time you wish, without giving a reason.

Cómo obtener más información

Pfizer CT.gov Call Center

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Study to Understand How the Study Medicine (PF-06823859) W…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.